biohacking$bioLLM CA: TBA

database / hormone

Bombesin

research compound hormone gastrointestinalnervous sequence not characterised
SOOOOOOOOOOOOOOOOOONNNNNNNNNNNNNNNNNNNNNNNNHHHHHHHHHHHHHHHHHHHHHHHHHHHH
114 heavy atoms · 227 bonds · drag to pan, scroll to zoom C71N24O18S1

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 16201612. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

Pyroglutamate N-terminus and C-terminal amide.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formulaC71H110N24O18S
molecular weight1619.9 Da (PubChem)
computed backbone massnot characterised
lengthnot characterised
net charge (pH 7.4)not characterised
mean hydropathynot characterised
half-lifenot characterised
delivery routenot characterised
PubChem CID16201612
PDBnot characterised
UniProt parentnot characterised

Mechanism

Binds mammalian bombesin-family receptors (GRPR/NMBR); a frog-skin peptide widely used as a research probe.

Reported targets: GRPR NMBR

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcomewhere it appears
gastrin release in modelsClinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT i… Clinical nuclear medicine 2026
satiety in modelsBombesin improves visceral hypersensitivity and colonic hyperpermeability vi… European journal of pharmacology 2026

Literature (8)

Clinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT in the Staging of Breast Cancer — Clinical nuclear medicine 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42305081 · DOI 10.1097/rlu.0000000000006582

Bombesin improves visceral hypersensitivity and colonic hyperpermeability via BB<sub>1</sub> receptor-dependent multi-pathway mechanisms in a rat model of irritable bowel syndrome — European journal of pharmacology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41548687 · DOI 10.1016/j.ejphar.2026.178566

Bombesin stimulates dorsal raphe nucleus serotonergic neurons via a mechanism involving BB1 receptors — General physiology and biophysics 2025

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 40114617 · DOI 10.4149/gpb_2025007

Biodistribution of the Bombesin Receptor-Targeted Radiopharmaceutical Precursor BBN/C1-C2 in a Prostate Cancer Model — Sovremennye tekhnologii v meditsine 2025

Gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor expressed in the central nervous system, the gastrointestinal tract, the pancreas, and the adrenal cortical tissue regulating their physiological functions. In addition to normal tissues, GRPR is overexpressed in many solid cancers. At present, several radiolabeled ligands targeting GRPR have been introduced into clinical practice for cancer diagnostics and radioligand therapy. However, there were found the high uptake of radiopharmaceuticals in normal organs and low bioavailability of the drugs caused by their stability. Therefore, GRPR radioantagonists with improved proteolytic stability and longer residence time in tumor foci with low uptake in non-target organs are currently being sought to improve the therapeutic efficacy. The aim of the study was to analyze the biodistribution of the BBN/C1-C2 molecule create…

open access ↗ · PMID 41684873 · DOI 10.17691/stm2025.17.6.03

Bombesin receptor-activated protein homolog deficiency reduces food intake and alleviates metabolic dysfunction in high-fat diet treated mice — Physiology & behavior 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41932562 · DOI 10.1016/j.physbeh.2026.115330

Linking GERD and the Peptide Bombesin: A New Therapeutic Strategy to Modulate Inflammatory, Oxidative Stress and Clinical Biochemistry Parameters — Antioxidants (Basel, Switzerland) 2024

Gastroesophageal reflux disease (GERD) represents one of the most prevalent foregut illnesses, affecting a large portion of individuals worldwide. Recent research has shown that inflammatory mediators such as cytokines, chemokines, and enzymes are crucial for causing esophageal mucosa alterations in GERD patients. It seems likely that the expression of various cytokines in the esophageal mucosa also induces oxidative stress by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). As humoral agents and peptidergic neurotransmitters that may support the enterogastric axis, bombesin and its related bombesin-like peptide, GRP (gastrin releasing peptide), have not been fully investigated. Therefore, considering all these assumptions, this study aimed to evaluate the influence of bombesin in reestablishing biochemical markers linked with inflammation a…

open access ↗ · PMID 39334702 · DOI 10.3390/antiox13091043

Development of bombesin-tubulysin conjugates using multicomponent chemistry to functionalize both the payload and the homing peptide — Frontiers in pharmacology 2024

Peptide-drug conjugates (PDCs) have recently gained significant attention for the targeted delivery of anticancer therapeutics, mainly due to their cost-effective and chemically defined production and lower antigenicity compared to ADCs, among other benefits. In this study, we designed and synthesized novel PDCs by conjugating new thiol-functionalized tubulysin analogs (tubugis) to bombesin, a peptide ligand with a relevant role in cancer research. Two tubulysin analogs bearing ready-for-conjugation thiol groups were prepared by an on-resin multicomponent peptide synthesis strategy and subsequently tested for their stand-alone in vitro anti-proliferative activity against human cancer cells, which resulted in IC50 values in the nanomolar range. In addition, various fluorescently labeled [K5]-bombesin(6-14) peptides, non-lipidated and lipidated with fatty acid chains of variable length, we…

open access ↗ · PMID 39600359 · DOI 10.3389/fphar.2024.1408091

Synthesis and Evaluation of Novel <sup>68</sup>Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe<sup>6</sup>,Pro<sup>14</sup>]Bombesin(6-14) and [d-Phe<sup>6</sup>,des-Met<sup>14</sup>]Bombesin(6-14) Sequences — Molecular pharmaceutics 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41607011 · DOI 10.1021/acs.molpharmaceut.5c01683

Related

Glucagon

hormone · 8 citations

Ghrelin

hormone · 8 citations

Oxytocin

hormone · 8 citations

Vasopressin

hormone · 8 citations

Gonadorelin

hormone · 8 citations

Kisspeptin-10

hormone · 8 citations